GlycoMimetics (NASDAQ:GLYC – Get Free Report) released its quarterly earnings results on Thursday. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.16) by $0.05, Zacks reports.
GlycoMimetics Trading Up 9.2 %
Shares of GlycoMimetics stock traded up $0.02 on Thursday, hitting $0.28. 725,304 shares of the company’s stock were exchanged, compared to its average volume of 305,374. GlycoMimetics has a 1 year low of $0.14 and a 1 year high of $3.36. The company has a 50-day simple moving average of $0.26 and a 200-day simple moving average of $0.24.
Analyst Ratings Changes
Separately, StockNews.com started coverage on GlycoMimetics in a report on Monday. They issued a “sell” rating on the stock.
About GlycoMimetics
GlycoMimetics, Inc, a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML.
Further Reading
- Five stocks we like better than GlycoMimetics
- How Can Investors Benefit From After-Hours Trading
- Upstart’s Uptrend Is Just Getting Started: Its Time to Load Up
- Stock Market Upgrades: What Are They?
- Archer Aviation Lands BlackRock Investment—What’s Next for ACHR?
- Are These Liquid Natural Gas Stocks Ready For An Upside Bounce?
- Buffett Buys More Occidental Petroleum—Sticking to His Playbook
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.
